Clinical Trials Using Durvalumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Durvalumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 126-131 of 131
< Previous 1 ... 4 5 6

  • Restorative Microbiota Therapy in Combination with Durvalumab with or without Chemotherapy for the Treatment of Stage IIIB-IV Non-small Cell Lung Cancer

    This phase II trial studies the effect, safety and tolerability of restorative microbiota therapy (RMT) in combination with durvalumab with or without chemotherapy in treating patients with stage IIIB-IV non-small cell lung cancer. RMT is prepared by extracting healthy bacteria from the stool of healthy human donors while rigorously testing samples for harmful bacteria and viruses before processing. The extract is then made into capsules which is taken by mouth. RMT may make immunotherapy more effective. Durvalumab is a type of anti-cancer therapy called immunotherapy that uses the patient’s own immune system to attack tumor cells. Chemotherapy drugs, such as cisplatin, pemetrexed, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving RMT may make durvalumab treatment with or without chemotherapy more effective in controlling stage IIIB-IV non-small cell lung cancer.
    Location: University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota

  • AVB-S6-500 and Durvalumab in Treating Patients with Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This trial studies the side effects and best dose of AVB-S6-500 when given together with durvalumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum therapy or has come back. Immunotherapy with AVB-S6-500 and durvalumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Danvatirsen and Durvalumab in Treating Patients with Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

    This phase II trial studies how well danvatirsen and durvalumab work in treating patients with pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer that has spread to other places in the body (advanced) and does not respond to treatment (refractory). Danvatirsen may be used to block the production of proteins needed for tumor cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving danvatirsen and durvalumab may work better at treating pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Durvalumab and Tremelimumab, Oleclumab, or Monalizumab in Treating Patients with Colorectal Cancer with Lung or Liver Metastases That Can Be Removed by Surgery

    This phase I trial studies the side effects and how well durvalumab and tremelimumab, oleclumab, or monalizumab work in treating patients with colorectal cancer that has spread to the lungs or liver (lung or liver metastases) and can be removed by surgery. Immunotherapy with monoclonal antibodies, such as durvalumab, tremelimumab, oleclumab, and monalizumab may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Short-term Fasting prior to Standard of Care PD-1 / PD-L1 Inhibitor Therapy for the Treatment of Advanced or Metastatic Skin Malignancy

    This phase I trial studies the side effects of short-term fasting in patients with skin malignancy that has spread to other places in the body (advanced or metastatic) treated with a PD-L1 or PD-1 inhibitor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, nivolumab, cemiplimab, avelumab, atezolizumab, or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Undergoing short-term fasting prior to treatment with one of these PD-L1 or PD-1 inhibitors may potentially reduce the side effects of immunotherapy or even improve the effectiveness of immunotherapy in patients with skin malignancy.
    Location: 2 locations

  • Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

    This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
    Location: OHSU Knight Cancer Institute, Portland, Oregon


< Previous 1 ... 4 5 6